Skip to main content
11 Mar | 2022

El BBRC participa a la 16a International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

The BarcelonaBeta Brain Research Center (BBRC) team will present four research papers at the 16th International Conference on Alzheimer’s and Parkinson’s Diseases (AD / PD 2022). The congress, which will take place from March 15 to 20 in Barcelona and also in hybrid format, online, is one of the main scientific meetings to discuss the mechanisms and treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. This edition will host three symposia and a poster of some of the latest BBRC findings:

  • Laura Stankeviciute, pre-doctoral researcher in the Neuroimaging Research Group, will present 'Associations between iron deposition in the brain and AD-like neuroimaging phenotypes in cogniteviley unimpaired adults' in the session AD, PD, LBD: Machine learning, deep learning, EEG, diagnosis.& clinical trials, held Friday 18.
  • Mahnaz Shekari, pre-doctoral researcher in the Neuroimaging Research Group, will give a talk on ‘Evaluating the sensitivity of cenriloid quantification to pipeline design’ at the AD, FTD, LBD diagnosis symposium. EEG & clinical trials & advances and drug development on Saturday 19th.
  • Dra. Marta del Campo, Head of Fluid Biomarkers Facility, will moderate the Fluid Biomarkers 2 symposium, where she will also present the talk ‘CFS proteome profiling reveals novel biomarkers for specific diagnosis of dementia with lewy bodies’ on Friday 18th.
  • Dra. Gemma Salvadó will present the poster ‘Increased plasma GFAP is associated with higher cerebral glucose consumption early in the Alzheimer's continuum’, which will be on display throughout the conference.

For the first time, this year AD / PD is also bringing together the Advances in Alzheimer’s Therapies Focus Meeting (AAT-AD / PD). The aim of the conference is to provide a space for medical and scientific professionals to discuss the latest advances in treatment, translational research, early diagnosis, drug development, and clinical trials of neurodegenerative diseases. Ultimately, AD / PD aims to foster the emergence of academia and industry partnerships that contribute to improving the lives of patients and families affected by neurogenerative diseases.

The full program of the conference is available at this link.